IBDEI367 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,50623,2)
 ;;=^5001814
 ;;^UTILITY(U,$J,358.3,50624,0)
 ;;=C92.A0^^193^2497^12
 ;;^UTILITY(U,$J,358.3,50624,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50624,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
 ;;^UTILITY(U,$J,358.3,50624,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,50624,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,50625,0)
 ;;=C92.51^^193^2497^13
 ;;^UTILITY(U,$J,358.3,50625,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50625,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,50625,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,50625,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,50626,0)
 ;;=C92.50^^193^2497^14
 ;;^UTILITY(U,$J,358.3,50626,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50626,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,50626,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,50626,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,50627,0)
 ;;=C94.40^^193^2497^17
 ;;^UTILITY(U,$J,358.3,50627,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50627,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,50627,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,50627,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,50628,0)
 ;;=C94.42^^193^2497^15
 ;;^UTILITY(U,$J,358.3,50628,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50628,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,50628,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,50628,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,50629,0)
 ;;=C94.41^^193^2497^16
 ;;^UTILITY(U,$J,358.3,50629,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50629,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,50629,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,50629,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,50630,0)
 ;;=D62.^^193^2497^18
 ;;^UTILITY(U,$J,358.3,50630,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50630,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,50630,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,50630,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,50631,0)
 ;;=C92.41^^193^2497^19
 ;;^UTILITY(U,$J,358.3,50631,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50631,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,50631,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,50631,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,50632,0)
 ;;=C92.40^^193^2497^20
 ;;^UTILITY(U,$J,358.3,50632,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50632,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,50632,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,50632,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,50633,0)
 ;;=D56.0^^193^2497^21
 ;;^UTILITY(U,$J,358.3,50633,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50633,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,50633,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,50633,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,50634,0)
 ;;=D63.1^^193^2497^23
 ;;^UTILITY(U,$J,358.3,50634,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50634,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,50634,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,50634,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,50635,0)
 ;;=D63.0^^193^2497^24
 ;;^UTILITY(U,$J,358.3,50635,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50635,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,50635,1,4,0)
 ;;=4^D63.0
